MRI and fMRI for Neuromodulation

Therapeutic Potential of Ultrasound Neuromodulation in Decreasing Neuropathic Pain: Clinical and Experimental Evidence

Background

For more than seven decades, ultrasound has been used as an imaging and diagnostic tool. Today, new technologies, such as focused ultrasound (FUS) neuromodulation, have revealed some innovative, potential applications. However, those applications have been barely studied to deal with neuropathic pain (NP), a cluster of chronic pain syndromes with a restricted response to conventional pharmaceuticals.

Objective

To analyze the therapeutic potential of low-intensity (LIFUS) and high-intensity (HIFUS) FUS for managing NP.

Methods

We performed a narrative review, including clinical and experimental ultrasound neuromodulation studies published in three main database repositories.

Discussion

Evidence shows that FUS may influence several mechanisms relevant for neuropathic pain management such as modulation of ion channels, glutamatergic neurotransmission, cerebral blood flow, inflammation and neurotoxicity, neuronal morphology and survival, nerve regeneration, and remyelination. Some experimental models have shown that LIFUS may reduce allodynia after peripheral nerve damage. At the same time, a few clinical studies support its beneficial effect on reducing pain in nerve compression syndromes. In turn, Thalamic HIFUS ablation can reduce NP from several etiologies with minor side-effects, but some neurological sequelae might be permanent. HIFUS is also useful in lowering non-neuropathic pain in several disorders.

Conclusion

Although an emerging set of studies brings new evidence on the therapeutic potential of both LIFUS and HIFUS for managing NP with minor side-effects, we need more controlled clinical trials to conclude about its safety and efficacy.

Evaluation of MRI Issues for a New Wirelessly Powered, Spinal Cord Stimulation Lead With Receiver

OBJECTIVE. MRI is an imaging modality frequently ordered for patients with neuromodulation systems implanted for spinal cord stimulation. The purpose of this investigation was to evaluate MRI safety issues (magnetic field interactions, MRI-related heating, functional disturbances, and artifacts) for a new wirelessly powered lead with receiver used for SCS. MATERIALS AND METHODS. Lead samples underwent in vitro evaluation for MRI safety issues using standardized techniques. Magnetic field interactions (i.e., translational attraction and torque) and artifacts were tested at 3 T. MRI-related heating was performed at 1.5 T/64 MHz and 3 T/128 MHz using two different methods: numerical simulations with analytical modeling and physical testing. Possible functional disturbances were evaluated under exposures to 1.5-T/64-MHz and 3-T/128-MHz MRI conditions. RESULTS. The lead exhibited minor magnetic field interactions (22° deflection angle, no torque) at 3 T. The highest temperature change recorded at 1.5 T/64 MHz and 3 T/128 MHz was 3.8°C and 11.3°C, respectively. Exposures to MRI conditions did not damage or alter the functional aspects of the leads. The maximum artifact size seen on a gradient-echo pulse sequence extended approximately 10 mm relative to the size of the lead. CONCLUSION. The MRI tests performed on patients with the new lead with receiver revealed no substantial concerns with respect to the conditions that we provide in the safety guidelines that were based on the results of this investigation. Therefore, MRI examinations will result in acceptable heating when conducted at appropriate whole-body-averaged specific absorption rate levels (i.e., 2.0 W/kg at 1.5 T/64 MHz and 0.3 W/kg at 3 T/128 MHz, corresponding to adjusted temperature rises of 3.6°C and 1.2°C, respectively). Therefore, patients with this wirelessly powered lead and receiver implanted can safely undergo MRI examinations under specific conditions.